AI in U.S. hospitals: systemic data silos, profit pressures, and regulatory gaps expose patient safety risks
Original framing: “STAT+: The whistleblower, The Lab, and the fine print” — STAT News
Rigorous validation studies of clinical AI are scarce, and existing trials frequently lack external replication and demographic diversity. Scientific best practices demand transparent reporting of performance metrics, bias assessments, and post‑deployment monitoring, which are currently under‑implemented.
The whistleblower case and related lawsuit expose a deeper architecture where profit‑driven AI vendors, lax regulatory oversight, and opaque data pipelines converge to jeopardize patient safety.
Historical precedents and cross‑cultural examples demonstrate that without transparent governance and inclusive design, technology reproduces existing inequities. By embedding Indigenous data sovereignty, rigorous scientific validation, and marginalized community feedback into an independent oversight framework, the health system can transform AI from a risk‑laden commodity into a public‑interest tool. Leveraging the trickster's paradoxical insight, stakeholders can disrupt complacent narratives and re‑center the human dimensions of care, ensuring that future AI deployments are accountable, equitable, and resilient.